Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cassava Sciences Inc
(NQ:
SAVA
)
21.71
-0.09 (-0.39%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Cassava Sciences Inc
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
18
19
Next >
12 Health Care Stocks Moving In Thursday's Intraday Session
November 04, 2021
Gainers Evaxion Biotech (NASDAQ:EVAX) stock moved upwards by 157.5% to $16.74 during Thursday's regular session. Evaxion Biotech's stock is trading at a volume of...
Via
Benzinga
Mid-Day Market Update: Gold Rises 1.7%; Lightspeed Commerce Shares Plunge
November 04, 2021
Midway through trading Thursday, the Dow traded down 0.25% to 36,068.78 while the NASDAQ rose 0.60% to 15,906.62. The S&P also rose, gaining 0.21% to 4,670.58. The U.S. has...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Cassava Stock Soars; Journal Finds No Proof Of Tampered Alzheimer's Data
November 04, 2021
The journal that published a disputed paper from Cassava said Thursday it found no evidence of data manipulation, leading SAVA stock to soar.
Via
Investor's Business Daily
Mid-Morning Market Update: Markets Mixed; Moderna Lowers Covid-19 Vaccine Sales Outlook
November 04, 2021
Following the market opening Thursday, the Dow traded down 0.20% to 36,086.70 while the NASDAQ rose 0.83% to 15,942.06. The S&P also rose, gaining 0.40% to 4,679.39. The U.S....
Via
Benzinga
Topics
Stocks
Exposures
COVID-19
US Equities
55 Stocks Moving In Thursday's Mid-Day Session
November 04, 2021
Gainers Evaxion Biotech A/S (NASDAQ: EVAX) shares climbed 179% to $18.17 after dropping over 10% on Wednesday. NerdWallet, Inc. (NASDAQ: NRDS) jumped 60% to $28.86 after the...
Via
Benzinga
Cassava Sciences Is on a Bumpy Road to Multibagger Status
November 03, 2021
Based on analyst estimates for the next ten years, SAVA stock could be worth three times more if its Alzheimer's drug succeeds.
Via
InvestorPlace
71 Biggest Movers From Yesterday
November 03, 2021
Gainers Avis Budget Group, Inc. (NASDAQ: CAR) shares climbed 108.3% to close at $357.17 on Tuesday after the company reported better-than-expected Q3 adjusted EPS and sales...
Via
Benzinga
SAVA Stock: 8 Things to Know as Cassava Sciences Rockets Higher
November 02, 2021
As investors bet that Cassava Sciences is on the cusp of a breakthrough with its Alzheimer's treatment, SAVA stock is gaining.
Via
InvestorPlace
What's Up With Cassava Sciences Flying Today?
November 02, 2021
Cassava Sciences Inc (NASDAQ: SAVA) shares are trading up Tuesday as traders were able to push the stock higher. The stock has been trending on social media sites such...
Via
Benzinga
Cassava Stock Could Jump More Than 200 Times
November 01, 2021
Cassava's Alzheimer's drug appears backed by strong data and plenty of public support. That's a winning combination for SAVA stock.
Via
InvestorPlace
Cassava Sciences’ Stock Remains an Enigma
November 01, 2021
Cassava Sciences has lost 26% for the month through Oct. 27. Entering October, SAVA stock looked to go on a big run. It did the opposite.
Via
InvestorPlace
Buy SAVA Stock on Dips as its Phase 3 Trial Moves Along
October 29, 2021
SAVA stock likely won't make another big move until Phase 3 trial data for Simulfilam comes in, so ease into it until then
Via
InvestorPlace
Athira CEO Resigns After Data Manipulation Firestorm, But Alzheimer's Stock Pops
October 22, 2021
Athira CEO Leen Kawas resigned after an investigation found she altered images.
Via
Investor's Business Daily
Jim Cramer Prefers Square To Marqeta, Recommends Trimming Positions In This Stock
October 22, 2021
On CNBC’s "Mad...
Via
Benzinga
Why Cortexyme Thinks It Could Be Next In The Mega Alzheimer's Drug Market
October 21, 2021
Cortexyme is testing a twice-day pill to treat Alzheimer's disease.
Via
Investor's Business Daily
3 Biotech Stocks That Are Ridiculously Overpriced
October 20, 2021
They've risen too far, too quickly.
Via
The Motley Fool
It Turns Out That The World Still Needs Coal: Good News For Our Recent Top Name, Peabody Energy
October 19, 2021
A Liebherr mining truck at dusk at Peabody's North Antelope Rochelle Mine in the Powder River Basin of Wyoming (photo via Peabody). It Turns Out The World...
Via
Benzinga
It Turns Out The World Still Needs Coal
October 19, 2021
Peabody Energy (BTU), whose shares spiked 23% on Monday after the company announced that its coal revenue in Q3 would be the highest in seven quarters and it offered bullish forward guidance.
Via
Talk Markets
Exposures
Coal
Crisis Investing
October 12, 2021
From COVID, to energy, to supply chain breakdowns, the market has been buffeted by crises recently. How we've navigated them so far.
Via
Talk Markets
Crisis Investing: From COVID, To Energy, To Supply Chain Breakdowns, The Market Has Been Buffeted By Crises Recently. How We've Navigated Them So Fa.
October 12, 2021
A Gadsden flag hung out of a Southwest Airlines 737 cockpit. Photo via American Greatness. A Market Buffeted By Bad News The apparent work slowdown at...
Via
Benzinga
Exposures
Labor
Cassava Sciences: Fine Trading Stock, Terrible Investment
October 11, 2021
SAVA stock may be fun to trade, but the long-term prognosis is grim
Via
InvestorPlace
Topics
Fraud
Exposures
Legal
Cassava Sciences Starts Late-Stage Simufilam Study In Alzheimer's Patients
October 06, 2021
Cassava Sciences Inc (NASDAQ: SAVA) initiated an initial Phase 3 efficacy study of simufilam, an investigational drug for patients with Alzheimer's disease....
Via
Benzinga
Cassava Sciences Stock Could Explode as FDA Approval Is a Real Possibility
October 06, 2021
SAVA stock is volatile but worthwhile as its Alzheimer's drug inches closer to commercialization. Risk tolerance is needed, though.
Via
InvestorPlace
Exposures
Product Safety
Rebuilding Connections, Fostering Growth: Synaptogenix Could Be A Beacon of Hope for Patients With Neurological Diseases
October 05, 2021
Image by Gerd Altmann from Pixabay How well we think, feel and act rests in the hands of trillions of tiny connectors in our minds. Synapses play an integral role in how we...
Via
Benzinga
How David Green Traded Moderna For A Big Profit On Monday Morning
October 04, 2021
David Green was back live trading on Benzinga TV on Monday morning. Here's a recap of what he traded and discussed. Big Winners Of The Day Green's best trade on...
Via
Benzinga
Use Cassava Sciences Stock Weakness as Buy Opportunity Ahead of Phase 3
October 04, 2021
If Cassava Sciences' Alzheimer drug can continue to produce solid results, it could see FDA approval before the end of 2022. SAVA stock may not be oversold for long.
Via
InvestorPlace
Exposures
Product Safety
What to Make of Cassava Sciences’ Late September Rally
October 04, 2021
Cassava Sciences gained 50% in the second half of September. Now the question is, can SAVA stock keep up momentum in October?
Via
InvestorPlace
Cassava Stock Has Reached a Positive Turning Point
October 01, 2021
Cassava is rebounding and SAVA stock may rally back to its old highs as it fends off a short-selling attack.
Via
InvestorPlace
The Good News Is Piling Up for Cassava Stock
October 01, 2021
Recent news indicates that the FDA is going to reject a petition against Cassava, helping to make SAVA stock very attractive.
Via
InvestorPlace
Exposures
Product Safety
Is Cassava Sciences Back in the Game?
September 28, 2021
There's nothing spectacular about the latest results for the company's flagship drug.
Via
The Motley Fool
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
18
19
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.